from LR Health & Beauty SE (isin : NO0013149658)
LR Health & Beauty SE publishes Q4 2025 report and advances financial and strategic initiatives
EQS-News: LR Health & Beauty SE / Key word(s): Quarter Results
LR Health & Beauty SE publishes Q4 2025 report and advances financial and strategic initiatives
24.02.2026 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
LR Health & Beauty SE publishes Q4 2025 report and advances financial and strategic initiatives
- FY 2025 sales reached EUR 277.1 million on a preliminary basis, with EBITDA reported of EUR 16.5 million
- Focus on implementing a new financing structure and initiating targeted strategic measures for long-term business development and growth
- Planned launch of new generation of products combining health and beauty expertise demonstrates innovative strength and sets important impulses for 2026
Ahlen, 24 February 2026 – LR Health & Beauty SE, Europe’s leading digital social commerce company for high-quality nutritional supplements and beauty products, today publishes its results for the fourth quarter of 2025 as well as preliminary sales and earnings results for the 2025 financial year.
The LR Group continued to face generally subdued consumer sentiment in Western European markets in the fourth quarter of 2025. LR Health & Beauty SE achieved sales (revenue from goods sold) of EUR 68.2 million in the fourth quarter 2025 (Q4 2024: EUR 76.5 million), representing a decrease of 10.9%. Accordingly, over the course of the full 2025 year, LR Health & Beauty SE posted a 4.6% year-on-year lower level of sales of EUR 277.1 million on a preliminary basis (2024: EUR 289.2 million).
Furthermore, LR Health & Beauty SE achieved EBITDA reported of EUR 0.3 million in the fourth quarter of 2025 (Q4 2024: EUR 8.3 million). The results in the final quarter were particularly affected by the lower sales level and exceptional items as part of the realignment of the financing structure. For the full 2025 year, reported EBITDA on a preliminary basis amounted to EUR 16.5 million compared with EUR 27.3 million in 2024. Normalized EBITDA in the fourth quarter of 2025 decreased to EUR 3.4 million, compared with EUR 9.5 million in the fourth quarter of the previous year. Accordingly, over the full course of 2025, normalized EBITDA amounted to EUR 22.5 million on the basis of preliminary figures (2024: EUR 32.6 million).
Jörg Körfer, CEO of LR Health & Beauty SE, comments: “In both financial and strategic terms, we are focusing consistently on creating the preconditions for sustainably positive business growth. We have recently reached an important milestone with the agreement concerning a realignment of the financing structure. At the same time, it is important in 2026 to advance the LR Group’s business with suitable strategic initiatives. One focus in this context is the further development of our product portfolio. In the spring, we are planning the promising launch of a new generation of products that combines expertise from the health and beauty areas and will provide our distribution partners with fresh impetus for their business activities.”
In developing high-quality dietary supplements and cosmetic products, LR regularly draws on the latest findings from science and research. Sustainability aspects are also given special consideration when optimising the product portfolio – including in the upcoming product launch.
The report for the fourth quarter of 2025 is available online from today on the company’s website at https://ir.lrworld.com/. The final, audited results for the 2025 financial year will be published at the end of April 2026 with the Annual Report on the company’s website.
LR Group
Under the motto “More quality for your life”, the LR Group – headquartered in the town of Ahlen/Westphalia – successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive Social Commerce Company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool “LR neo” offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.
Since 1985, LR has been firmly established in the market as a “people business” with a focus on people and personal consultation. In times of changing working environments, the business model is particularly appealing to those who are looking for more flexibility, a better work-life balance and greater financial independence.
The processing of aloe vera has been one of LR’s core competencies for over 20 years. Only the leaf’s valuable inside is used for the products. In Ahlen, the company has built one of the most modern aloe vera production facilities for aloe vera drinking gels in Europe.
In the fall of 2009, LR founded the LR Global Kids Fund e.V., which supports disadvantaged children and their families in many countries around the world efficiently and without the usual red tape in cooperation with local institutions. For further information on our commitment to sustainability, please read our Sustainability Report.
Contact:
PR Contact:
LR Health & Beauty SE
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone: +49(0)2382 7658-106
E-mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/
IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Building D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
24.02.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News
| Language: | English |
| Company: | LR Health & Beauty SE |
| Kruppstr. 55 | |
| 59227 Ahlen | |
| Germany | |
| Phone: | +49 238270600 |
| E-mail: | info@lrworld.com |
| Internet: | www.lrworld.com |
| ISIN: | NO0013149658 |
| WKN: | A3H3FM |
| Listed: | Regulated Unofficial Market in Frankfurt; Stockholm |
| EQS News ID: | 2280276 |
| End of News | EQS News Service |
2280276 24.02.2026 CET/CEST